 And the new foray is with the new immunotherapeutic agents, not the old drugs with interferon, to look into some of these newer agents that target immune checkpoints, NTA-PD1 and NTA-PDL1. And the hope that maybe we can combine these new immunotherapeutic agents with the target agents that we have, we will be able to maximize on benefit and have synergy, produce synergy, which is what we really hope to see, which is A plus B is going to be better than A followed by B. So in a capsule, this basically, these were the results from the best trial.